AzTrials
AzTrials

Hematological MalignanciesPhase 1/2NCT02828878

Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

A Phase 1/2 study testing Allogeneic MPBC transplantation from matched related donor in people with Hematological Malignancies, run by Cellect Biotechnology at 2 sites in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Interventional, open label, Phase I/II, Safety and Proof-of-Concept Study, with a follow up period of 180 days after the transplantation of ApoGraft. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Hematological Malignancies
What is being tested?
Allogeneic MPBC transplantation from matched related donor
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
2 sitesIsrael
Study dates
Jan 2017to Jul 2020
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Recipient/patient main inclusion criteria:

  1. Adult male or female subjects, 18-70 years of age.
  2. Subjects are eligible for allogeneic HLA-matched related HSCT for any hematological malignancies for which transplantation is appropriate with corresponding related donor. One of the following hemato-oncology disorders diagnosis is required:
  • Acute myelogenous leukemia (AML) and Acute lymphoblastic leukemia (ALL) in 1st or subsequent complete remission (CR)
  • Non-Hodgkin's disease (NHD) in CR by CT or PET/CT
  • Hodgkin's disease (HD) in 1st or subsequent CR by CT or PET/CT
  • Intermediate, High or Very High Risk Myelodysplastic syndrome (MDS) (IPSS-R criteria)
  1. The donor and recipient must have full match at the HLA A, B, C, DR and DQ loci.
  2. ECOG performance status score 0-1 at time of the screening visit.
  3. Subjects must have adequate organ function as defined in the study protocol
  4. Signed written informed consent to participate in the study.
  5. If female of childbearing potential, agree to use an acceptable method of birth control or be surgically sterile, and have a negative pregnancy test.

Donor main inclusion criteria:

  1. Adult male or female subjects, 18-65 years of age.
  2. Donor criteria according to standard WMDA criteria for donor selection. 3 Must have full match at the HLA A, B, C, DR and DQ loci with the recipient.
  3. Signed written informed consent

Recipient/patient main exclusion criteria:

  1. Use of non-myeloabletive conditioning.
  2. Uncontrolled infections including sepsis, pneumonia with hypoxemia, persistent bacteremia, or meningitis within two weeks of the screening visit.
  3. Current known acute or chronic infection with HBV or HCV.
  4. Known human immunodeficiency virus (HIV) infection or AIDS.
  5. Subjects with severe or symptomatic restrictive or obstructive lung disease or respiratory failure requiring ventilator support.
  6. Subjects with other concurrent severe and/or uncontrolled medical condition, which could compromise participation in the study (i.e. active infection, uncontrolled diabetes, uncontrolled hypertension, congestive cardiac failure, unstable angina, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months and chronic liver or renal disease.
  7. Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder or any chronic condition susceptible, in the opinion of the investigator, of interfering with the conduct of the study.
  8. Organ allograft or previous history of allogeneic stem cell transplantation.
  9. Pregnancy or lactation.

Donor main exclusion criteria:

  1. HIV, HBV or HCV positive subjects.
  2. Pregnant or lactating women.
  3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Trial locations and contacts

2 sites in 1 country.

Shai Yarkoni, MD contact

972-9-9741444

shai@cellect.co

Israel2 sites, 2 recruiting
  • Rambam Health Care Campus

    Haifa

    Tsila Zuckerman, MD

    Recruiting
  • Hadassah Medical Center, Ein Kerem, Jerusalem

    Jerusalem

    Polina Stephanski, MD

    Recruiting

Other trials in Israel

About this study

Official title: An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)

Interventional, open label, Phase I/II, Safety and Proof-of-Concept Study, with a follow up period of 180 days after the transplantation of ApoGraft.

Read the detailed description

ApoGraft product is a mobilized peripheral blood cell product of a matched Related donor, collected via apheresis, which is exposed to the apoptotic mediator Fas Ligand (CD95L) prior to transplantation (Ex Vivo).

The study is designed to address the aspects of engraftment and Prevention of Acute Graft versus Host Disease (aGvHD) rate and/or severity in 12 Patients

STUDY DESIGN:

This is a phase 1/2, open-label, proof-of-concept, staggered 4-cohort clinical study. Each cohort will include 3 patients with hemato-oncology disorders eligible for allogeneic HLA-matched HSCT. Patients in all cohorts will undergo similar study procedures and evaluation. The cohorts will differ from each other in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplantation and HSCT, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3 and 100 ng/ml APO010 in Cohort 4. APO010 is washed-out as part of the ApoGraft process and only trace amounts of APO010 are present in the final ApoGraft product

The study consists of a screening phase (subject and donor clinical assessment and screening tests), transplantation of ApoGraft, and a follow-up period of 180 days during and after hospitalization.

The study will progress from one cohort to the next based on an independent data safety monitoring board (DSMB) review and analysis of safety data

Being tested
Allogeneic MPBC transplantation from matched related donor
Keywords
Apoptosis, FAS Ligand, Bone marrow transplantation, GvHD, Stem cells
Medical subject headings
Hematologic Neoplasms, Autoimmune Lymphoproliferative Syndrome, Type IB

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Allogeneic MPBC transplantation from matched related donorBiological

Study groups in NCT02828878
Study groupRoleWhat they receive
ApoGraftExperimentalApoGraft is a mobilized peripheral blood cell (MPBC) product derived from peripheral blood. There will be 4 cohorts, each differ in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplant, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3, and 100 ng/ml APO010 in Cohort 4
Receives: Biological: Allogeneic MPBC transplantation from matched related donor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall incidence, frequency and severity of adverse events (AEs) potentially related to the product during the study

    Measured: 180 days from transplantation

Secondary outcomes (10)
  1. Determination of the optimal dose of FasL concentration that facilitates the biological activity of the ApoGraft process

    Measured: 180 days from transplantation

  2. Time of neutrophils engraftment determined by number of days for reaching first of 3 consecutive days with ANC ≥ 500/mm3

    Measured: 28 days from transplantation

  3. Rate of neutrophils engraftment determined by number of days for reaching first of 3 consecutive days with ANC ≥ 500/mm3

    Measured: 28 days from transplantation

  4. Time of platelets engraftment determined by number of days for reaching first of 3 consecutive days with platelets ≥ 20,000/mm3 in the absence of platelet administration during the prior 7 days

    Measured: 180 days from transplantation

  5. Rate of platelets engraftment determined by number of days for reaching first of 3 consecutive days with platelets ≥ 20,000/mm3 in the absence of platelet administration during the prior 7 days

    Measured: 180 days from transplantation

  6. Incidence to development of aGvHD

    Measured: 180 days from transplantation

  7. Time to development of aGvHD

    Measured: 180 days from transplantation

  8. Non-relapse mortality

    Measured: 180 days from transplantation

  9. Proportion of patients with disease relapse

    Measured: 180 days from transplantation

  10. Proportion of patients with progression free and overall survival

    Measured: 180 days from transplantation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jul 2016 (estimated)
  2. Study startJan 2017
  3. Primary completionJul 2020 (estimated)
  4. Study completionJul 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
12 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02828878
Sponsor's protocol ID
ApoGraft 01
Status last verified
Nov 2019
First submitted
4 Jul 2016
Last updated
26 Nov 2019
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Allogeneic MPBC transplantation from matched related donor in people with Hematological Malignancies, run by Cellect Biotechnology at 2 sites in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Shai Yarkoni, MD (972-9-9741444, shai@cellect.co), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall incidence, frequency and severity of adverse events (AEs) potentially related to the product during the study (time frame: 180 days from transplantation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in